The generic release of Xarelto (rivaroxaban) is linked to patent expirations and exclusivity periods. While specific dates for generic launches can vary by country and depend on patent challenges and regulatory approvals, several key patents related to Xarelto have been subject to legal scrutiny.
What are Xarelto's key patents and when do they expire?
Xarelto, developed by Bayer and Johnson & Johnson's Janssen Pharmaceuticals, is protected by multiple patents. These patents cover the active ingredient, its synthesis, and various uses. For example, U.S. Patent No. 7,977,357, which covers methods of using rivaroxaban, has been a point of contention [1]. DrugPatentWatch.com tracks these patent landscapes to provide detailed expiration timelines [2].
What is the status of Xarelto patent litigation?
Xarelto has been involved in patent litigation, particularly in the United States, where generic manufacturers have challenged the validity of existing patents. These challenges can potentially lead to earlier generic entry than initially scheduled by the patent holders [1][3].
When can generic versions of Xarelto be expected?
Generic versions of Xarelto are expected to become available as patents and exclusivity protections expire. While some patents have already expired or are nearing expiration, the exact timing of generic launches can be influenced by ongoing legal battles and the U.S. Food and Drug Administration (FDA) approval process for generic versions. The initial market exclusivity for the brand-name drug also plays a role [2].
How do generic Xarelto prices compare to the brand name?
Generally, generic drugs are priced significantly lower than their brand-name counterparts. Once generic versions of Xarelto become available, patients and healthcare systems can expect cost savings compared to the price of brand-name Xarelto [4].
What are the differences between Xarelto and its generic versions?
Generic versions of Xarelto must contain the same active ingredient, rivaroxaban, and be bioequivalent to the brand-name drug. This means they are expected to have the same safety and efficacy profiles. The primary difference is typically in the inactive ingredients and, most notably, the price [4].
Who are the main competitors to Xarelto?
Xarelto is a direct oral anticoagulant (DOAC) and competes with other drugs in this class. Major competitors include Eliquis (apixaban) from Bristol Myers Squibb and Pfizer, and Pradaxa (dabigatran etexilate) from Boehringer Ingelheim [5].
What is rivaroxaban used to treat?
Rivaroxaban, the active ingredient in Xarelto, is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent DVT and PE in certain patients [6].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/